Last $66.34 USD
Change Today +0.78 / 1.19%
Volume 2.0M
DGX On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Open
$65.90
Previous Close
$65.56
Day High
$66.84
Day Low
$65.51
52 Week High
12/19/14 - $66.84
52 Week Low
02/7/14 - $50.46
Market Cap
9.6B
Average Volume 10 Days
1.4M
EPS TTM
$4.05
Shares Outstanding
144.5M
EX-Date
01/9/15
P/E TM
16.4x
Dividend
$1.32
Dividend Yield
1.94%
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. It offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; and risk assessment services for the life insurance industry. The company also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, it provides molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the brand names of Atria and AlleleSeqr. Further, the company offers Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, including vital signs and progress notes; and ChartMaxx, an electronic document management system for hospitals. The company offers its diagnostic information services to patients, physicians, hospitals, integrated delivery networks, health plans, employers, and others through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

41,000 Employees
Last Reported Date: 02/18/14
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $472.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $573.9K
Senior Vice President of Clinical Franchises
Total Annual Compensation: $520.0K
Senior Vice President and General Counsel
Total Annual Compensation: $492.1K
Compensation as of Fiscal Year 2013.

quest diagnostics inc (DGX) Key Developments

Quest Diagnostics Receives FDA Clearance for Simplexa Flu A/B & RSV Direct Test to Include Eight Circulating Influenza Viruses

Quest Diagnostics announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter. The FDA, which granted 510(k) clearance to the test kit originally in July 2012, cleared additional analytical reactivity to include Flu A H7N9 and H3N2v, among other strains, based on studies that demonstrated the test's analytical performance. The Simplexa Flu A/B & RSV Direct kit on the 3M Integrated Cycler is a real-time RT-PCR molecular test that was 510(k) cleared by the FDA in July 2012 for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus and respiratory syncytial virus RNA in nasopharyngeal swabs from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors. Simplexa Flu A/B & RSV Direct was one of the first to be FDA cleared for molecular detection of influenza A, B and respiratory syncytial virus. The performance characteristics of the test with clinical specimens that are positive for novel avian influenza have not been established. The test kit with the eight additional strains is now available directly in the United States and internationally through the global distribution network of Focus Diagnostics. Classified as CLIA moderate complexity, the test can report results in about an hour through a proprietary process that eliminates nucleic acid extraction, a time consuming technique typically employed by molecular tests. Influenza viruses constantly change, causing the regular appearance of novel strains. The additional eight strains for which FDA cleared analytical reactivity are: H7N9, H3N2 as well as H1N1 (2011), H3N2 and influenza B. Of particular concern are the novel avian influenza A strain H7N9, which can cause death in as many as one third of infected patients, and the H3N2v, which infects humans more easily than other swine influenza virus.

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 28, 2015

Quest Diagnostics announced that its board of directors declared a quarterly cash dividend of $0.33 per share, payable on January 28, 2015 to shareholders of record of company's common stock on January 13, 2015.

Quest Diagnostics Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 09:30 AM

Quest Diagnostics Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 09:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Mark J. Guinan, Chief Financial Officer and Senior Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $66.34 USD +0.78

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid $54.30 USD +0.35
Covance Inc $103.17 USD -0.35
Hologic Inc $26.93 USD -0.03
Laboratory Corp of America Holdings $105.80 USD -0.64
QIAGEN NV €19.25 EUR +0.202
View Industry Companies
 

Industry Analysis

DGX

Industry Average

Valuation DGX Industry Range
Price/Earnings 19.1x
Price/Sales 1.3x
Price/Book 2.3x
Price/Cash Flow 16.0x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.